Menza hit the nail on the head.
It will be the fall in prescriptions written by doctors that will put the lid on any possible share price recovery.
Axiron should only be available by prescription for those with a medical condition that cannot produce the desirable amount of testosterone. It is not meant to be an aphrodisiac for sexual olympics.
Shareholders are waiting for a miracle that is not on the horizon & are better off looking elsewhere as the share price may never recover.
Add to My Watchlist
What is My Watchlist?
